July 2022 is Sarcoma Cancer Awareness Month and at Frontiers in Endocrinology we want to highlight the recent discoveries in the field and raise awareness of the importance of early diagnosis of these cancers.
Sarcomas is the general term for rare kinds of cancer growing in the bone and connective tissues. These tumors can be divided into two main groups, soft tissue sarcomas, and bone sarcomas. Interestingly, a new kind of sarcoma has been recently described, called pseudoendocrine sarcoma. The most common tissues affected by this kinds of sarcoma are bones, muscles, tendons, cartilage, nerves, fat, and blood vessels of your arms and legs, as well as many endocrine organs. It affects mainly children, adolescents, and adults under the age of 30, and represents 1% to 2% of all cancers. Symptoms vary depending on the part of the body that is affected, and prompt therapies are primary for increasing the survival rate of the patients. Most of the treatments for this kinds of cancers may include chemotherapy, radiation therapy and surgery. Recently, hormonal therapy has revealed to be a great strategy for the treatment of some of these tumors, especially for uterine and endometrial stromal sarcomas.
Moreover,
It is in this spirit that Frontiers is launching a new article collection to coincide with this Awareness Month. This occasion not only offers an opportunity to acknowledge soft tissue and bone sarcomas, but also to consider the importance of new research toward innovative diagnosis and treatment options.
This Frontiers in Endocrinology Research Topic aims to address the Cancer Endocrinology-specific dimensions of this Awareness Month, highlighting the importance of sarcoma research and considering how to improve early diagnosis and treatment options.
July 2022 is Sarcoma Cancer Awareness Month and at Frontiers in Endocrinology we want to highlight the recent discoveries in the field and raise awareness of the importance of early diagnosis of these cancers.
Sarcomas is the general term for rare kinds of cancer growing in the bone and connective tissues. These tumors can be divided into two main groups, soft tissue sarcomas, and bone sarcomas. Interestingly, a new kind of sarcoma has been recently described, called pseudoendocrine sarcoma. The most common tissues affected by this kinds of sarcoma are bones, muscles, tendons, cartilage, nerves, fat, and blood vessels of your arms and legs, as well as many endocrine organs. It affects mainly children, adolescents, and adults under the age of 30, and represents 1% to 2% of all cancers. Symptoms vary depending on the part of the body that is affected, and prompt therapies are primary for increasing the survival rate of the patients. Most of the treatments for this kinds of cancers may include chemotherapy, radiation therapy and surgery. Recently, hormonal therapy has revealed to be a great strategy for the treatment of some of these tumors, especially for uterine and endometrial stromal sarcomas.
Moreover,
It is in this spirit that Frontiers is launching a new article collection to coincide with this Awareness Month. This occasion not only offers an opportunity to acknowledge soft tissue and bone sarcomas, but also to consider the importance of new research toward innovative diagnosis and treatment options.
This Frontiers in Endocrinology Research Topic aims to address the Cancer Endocrinology-specific dimensions of this Awareness Month, highlighting the importance of sarcoma research and considering how to improve early diagnosis and treatment options.